Corvus Pharmaceuticals to Present at Jefferies Health Conference

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company based in Burlingame, California, has announced key participations in the upcoming Jefferies Global Health Conference. The company's president and CEO, Dr. Richard A. Miller, along with Chief Business Officer Jeffrey Arcara, will engage in one-on-one investor meetings and present a comprehensive corporate overview at the event. Scheduled to take place in New York from June 5-7, 2024, Corvus Pharmaceuticals' presentation is set for Wednesday, June 5, at 3:00 pm ET. 

The presentation will be accessible via a live webcast, which will also be available for 90 days post-event, through the company's investor relations section on its website.

Corvus Pharmaceuticals is noted for its cutting-edge work in immunotherapy, particularly through the development of ITK inhibition for treating various cancers and immune disorders. The company's leading product candidate, soquelitinib, is an oral small molecule drug that specifically targets ITK. Corvus has additional clinical-stage candidates aimed at different cancer treatments, underscoring its commitment to innovative therapeutic solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!